angiotensin ii, des-phe(8)- has been researched along with Cancer of Prostate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domińska, K; Habrowska-Górczyńska, DE; Kowalska, K; Ochędalski, T; Okła, P; Piastowska-Ciesielska, AW; Urbanek, KA | 1 |
| Gallagher, PE; Krishnan, B; Tallant, EA; Torti, FM | 1 |
| Dubey, P; Gallagher, PE; Krishnan, B; Smith, TL; Tallant, EA; Torti, FM; Willingham, MC; Zapadka, ME | 1 |
3 other study(ies) available for angiotensin ii, des-phe(8)- and Cancer of Prostate
| Article | Year |
|---|---|
Angiotensin 1-7 modulates molecular and cellular processes central to the pathogenesis of prostate cancer.
Topics: Angiotensin I; Cell Adhesion; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Extracellular Matrix Proteins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Peptide Fragments; Prostatic Neoplasms; RNA, Messenger; Signal Transduction | 2018 |
Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
Topics: Adenocarcinoma; Angiotensin I; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Peptide Fragments; Placenta Growth Factor; Pregnancy Proteins; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2013 |
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
Topics: Adenocarcinoma; Aged; Angiotensin I; Animals; Antineoplastic Agents; Bone Marrow Cells; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Humans; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Metastasis; Osteoclasts; Peptide Fragments; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |